Association Review
In brief
The association between KRAS (KRAS Proto-Oncogene, GTPase) and Pancreatic Adenocarcinoma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
3
Compounds
4
Trials
175of 8,022 via KRAS compounds
Publications
0
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Pancreatic Adenocarcinoma
The disorder
5 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Mechanism overlap
Shared mechanisms
1 shared pathway
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access
06
Interventions
Therapeutics
4 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
8,022 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
08
Provenance
References & sources
8 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access